multiple indications (Crohn's disease, ulcerative colitis, juvenile idiopathic arthritis, hidradenitis suppurativa, plaque psoriasis)
Rheumatology · 2018–2018
1decision
1medicine
0carried consumer input
0individual submissions
No submission for this condition has carried consumer input, including the one made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| adalimumab New formulations (20 mg/0.2 mL and 80 mg/0.8 mL) for severe Crohn's disease, moderate to severe ulcerative colitis, severe active juvenile idiopathic… | Jul 2018 | Recommended with restriction | none received |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.